Mineralys Therapeutics, Inc. $MLYS Shares Purchased by DAFNA Capital Management LLC

Key Points

• DAFNA Capital Management LLC increased its stake in Mineralys Therapeutics by 111.1% in the first quarter, owning approximately 0.48% of the company's shares valued at $4.91 million.
• Insiders at Mineralys Therapeutics, including CEO Jon Congleton, reported significant stock sales recently, adding to a total of 123,051 shares sold in the last ninety days.
• Mineralys Therapeutics has an average rating of "Moderate Buy" from analysts, with a consensus target price of $34.40.

DAFNA Capital Management LLC boosted its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 111.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 309,200 shares of the company's stock after acquiring an additional 162,700 shares during the quarter. Mineralys Therapeutics accounts for 1.4% of DAFNA Capital Management LLC's holdings, making the stock its 20th largest position. DAFNA Capital Management LLC owned approximately 0.48% of Mineralys Therapeutics worth $4,910,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. raised its position in Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company's stock valued at $25,000 after acquiring an additional 1,190 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Mineralys Therapeutics during the fourth quarter valued at approximately $48,000. CWM LLC raised its position in Mineralys Therapeutics by 59.3% during the first quarter. CWM LLC now owns 8,342 shares of the company's stock valued at $132,000 after acquiring an additional 3,105 shares in the last quarter. GAMMA Investing LLC raised its position in Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock valued at $140,000 after acquiring an additional 8,738 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in Mineralys Therapeutics during the fourth quarter valued at approximately $128,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock traded up $0.39 during trading on Wednesday, reaching $29.25. 8,642,758 shares of the company were exchanged, compared to its average volume of 1,019,113. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $32.00. The company has a market capitalization of $1.94 billion, a P/E ratio of -8.22 and a beta of -0.29. The stock's 50 day simple moving average is $14.48 and its two-hundred day simple moving average is $14.06.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.12. As a group, equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MLYS. Guggenheim set a $48.00 price target on Mineralys Therapeutics and gave the company a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Wednesday, August 13th. Bank of America raised their price objective on Mineralys Therapeutics from $38.00 to $43.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Jefferies Financial Group raised their price objective on Mineralys Therapeutics from $15.00 to $26.00 and gave the company a "hold" rating in a report on Wednesday. Finally, Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.60.

Insider Buying and Selling at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 59,925 shares of the business's stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $14.76, for a total value of $884,493.00. Following the sale, the chief financial officer owned 132,934 shares in the company, valued at approximately $1,962,105.84. The trade was a 31.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Malcom Rodman sold 11,365 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $12.93, for a total value of $146,949.45. Following the completion of the sale, the insider owned 92,891 shares in the company, valued at $1,201,080.63. This represents a 10.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 123,051 shares of company stock worth $1,776,262 over the last quarter. 25.56% of the stock is currently owned by company insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.